Literature DB >> 23696480

The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1 778 patients.

K Pazaitou-Panayiotou1, P Kappa Iliadou, A Chrisoulidou, P Mitsakis, E Doumala, A Fotareli, M Boudina, L Mathiopoulou, F Patakiouta, K Tziomalos.   

Abstract

AIM: Thyroid cancer incidence has been increased over the last decades. The aims of the present study were: (a) to identify a changing trend in thyroid cancer in Northern Greece, (b) to examine patients' and tumoral characteristics and (c) to investigate the increase of papillary microcarcinomas and that of invasive or larger cancers. PATIENTS AND METHODS: We retrospectively analyzed the records of 1 778 patients who were diagnosed with thyroid cancer between January 1971 and December 2010. The study period was divided into 4 decades: 1971-1980, 1981-1990, 1991-2000, 2001-2010. Patients were separated into 2 groups: in Group A we have included papillary thyroid microcarcinomas (PTM) and in Group B all cancers with diameter >10 mm as well as invasive cancers ≤10 mm.
RESULTS: Patients diagnosed with thyroid cancer increased substantially per decade. The relative frequency of papillary thyroid cancer cases increased (from 60% up to 84.6% in the last decade) and follicular cancers decreased (from 40% down to 11.6%). During the study period, cancer size declined. Frequency of PTM (Group A) increased from 0% up to 19.3% in the last decade, but cancers of this group represent only a minority of total cancers.
CONCLUSIONS: The increase of thyroid cancer in this cohort was mainly due to tumors larger than 1 cm and also to smaller in size but invasive thyroid tumors. This increase outnumbers the increase in papillary thyroid microcarcinomas. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23696480     DOI: 10.1055/s-0033-1345125

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  9 in total

1.  Geospatial and Temporal Analysis of Thyroid Cancer Incidence in a Rural Population.

Authors:  John P Hanley; Erin Jackson; Leslie A Morrissey; Donna M Rizzo; Brian L Sprague; Indra Neil Sarkar; Frances E Carr
Journal:  Thyroid       Date:  2015-06-02       Impact factor: 6.568

2.  Interleukin 27 -964A > G genetic polymorphism and serum IL-27p28 levels in Chinese patients with papillary thyroid cancer.

Authors:  Shulong Zhang; Xueren Gao; Yong Wang; Jianguang Jia; Qiang Zhang; Zhenling Ji
Journal:  Tumour Biol       Date:  2015-05-21

3.  Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.

Authors:  Hong Jin; Yundan Liang; Xunli Wang; Jingqiang Zhu; Ruifen Sun; Peng Chen; Xinwen Nie; Linbo Gao; Lin Zhang
Journal:  Med Oncol       Date:  2014-09-09       Impact factor: 3.064

4.  Association between the increase in incidence of papillary thyroid carcinoma in Crete and exposure to radioactive agents.

Authors:  E P Prokopakis; A Kaprana; A Karatzanis; G A Velegrakis; J Melissas; G Chalkiadakis
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-02-28       Impact factor: 2.124

5.  Circulating adipokines and metabolic setting in differentiated thyroid cancer.

Authors:  Chiara Mele; Maria Teresa Samà; Alessandro Angelo Bisoffi; Marina Caputo; Valentina Bullara; Stefania Mai; Gillian Elisabeth Walker; Flavia Prodam; Paolo Marzullo; Gianluca Aimaretti; Loredana Pagano
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

6.  A shift to more targeted thyroidectomies increased the detection of thyroid cancer and in particular low-risk papillary tumors in Southwestern Greece the decade 2007 to 2016.

Authors:  Georgios K Markantes; Stylianos Tsochatzis; Konstantinos Panagopoulos; Maria Melachrinou; Venetsana E Kyriazopoulou; Kostas B Markou; Marina A Michalaki
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-24

7.  The role of metabolic setting in predicting the risk of early tumour relapse of differentiated thyroid cancer (DTC).

Authors:  Chiara Mele; Marina Caputo; Maria Teresa Samà; Valentina Bullara; Maria Grazia Mauri; Flavia Prodam; Gianluca Aimaretti; Loredana Pagano; Paolo Marzullo
Journal:  Eur J Clin Nutr       Date:  2020-06-09       Impact factor: 4.016

8.  The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer.

Authors:  Danuta Gąsior-Perczak; Iwona Pałyga; Monika Szymonek; Artur Kowalik; Agnieszka Walczyk; Janusz Kopczyński; Katarzyna Lizis-Kolus; Tomasz Trybek; Estera Mikina; Dorota Szyska-Skrobot; Klaudia Gadawska-Juszczyk; Stefan Hurej; Artur Szczodry; Anna Słuszniak; Janusz Słuszniak; Ryszard Mężyk; Stanisław Góźdź; Aldona Kowalska
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

9.  Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis.

Authors:  Aliki Economides; Konstantinos Giannakou; Ioannis Mamais; Panayiotis A Economides; Panagiotis Papageorgis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-30       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.